Wikidata

(Q58614658)

English

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

scientific article published on 06 September 2011

In more languages
default for all languages
No label defined

No description defined

Statements

title
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors (English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
21900113
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21900113%20AND%20SRC:MED&resulttype=core&format=json
retrieved
12 February 2020
author name string

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q58614658&oldid=2178764367"